In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pink Sheet Team

Editorial Team

International

The policy and regulatory insights advantage for biopharma decision-makers around the globe.

Latest From Pink Sheet Team

Pink Sheet Podcast: Drug Pricing Reforms, Opioid Prescriber Education, China And FDA’s Project Orbis

Pink Sheet reporters and editors discuss new developments in US drug pricing reform, FDA considering mandatory opioid prescriber education again, and including China in the agency’s international parallel review initiative, Project Orbis.

Pricing Debate Drug Review

In Case You Missed It … News About Real-World Evidence, Pharmacovigilance, And More

We clean out your Labor Day inbox so you don't have to.

Pink Sheet Podcast: Gene Therapy In Europe, Lilly’s Olympic TV Ads, 'Most Favored Nation' Rule

Pink Sheet reporters and editors discuss Bluebird Bio’s decision to pull its gene therapy business from Europe, Eli Lilly potentially pushing regulatory boundaries with its Olympic TV spots, and the CMS decision to scrap the Trump aministration’s most favored nation reimbursement rule.

Commercial Strategies Gene Therapy

Podcast: What's Ahead For Aduhelm's Launch And Reimbursement

Pink Sheet and Scrip editors join Datamonitor Healthcare analysts to discuss Biogen's Aduhelm for Alzheimer's disease, including the expected launch trajectory, early commercial barriers to uptake and the Medicare reimbursement environment.

Medicare Neurology

Pink Sheet Podcast: First Interchangeable Biosimilar, Alzheimer’s At CMS, COVID-19 Vaccines In Kids

Pink Sheet reporters and editors discuss Viatris receiving the first interchangeable biosimilar designation, CMS hearing from stakeholders about Aduhelm and other Alzheimer’s drugs, and concerns about expanding pediatric coronavirus vaccine trials to look for rare adverse events.

Biosimilars Vaccines

Pink Sheet Podcast: As Aduhelm Turns, Teva Sues Under CREATES Act, Neulasta Untitled Letter

Pink Sheet reporters and editors discuss another explanation of the FDA’s Aduhelm label, the first lawsuit attempting to force the sale of samples for generic development, and the agency questioning promotion of Amgen’s Neulasta.

Neurology Legal Issues
See All
UsernamePublicRestriction

Register